Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD

6.74  -0.18 (-2.6%)

After market: 6.7023 -0.04 (-0.56%)

Fundamental Rating

2

CADL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. While CADL seems to be doing ok healthwise, there are quite some concerns on its profitability. CADL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CADL had negative earnings in the past year.
CADL had a negative operating cash flow in the past year.
CADL had negative earnings in each of the past 5 years.
CADL had a negative operating cash flow in each of the past 5 years.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of CADL (-41.27%) is comparable to the rest of the industry.
CADL has a better Return On Equity (-53.00%) than 63.62% of its industry peers.
Industry RankSector Rank
ROA -41.27%
ROE -53%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

CADL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, CADL has more shares outstanding
Compared to 5 years ago, CADL has more shares outstanding
CADL has a better debt/assets ratio than last year.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CADL has an Altman-Z score of 7.05. This indicates that CADL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.05, CADL belongs to the top of the industry, outperforming 82.62% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that CADL is not too dependend on debt financing.
CADL has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 7.05
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.64 indicates that CADL has no problem at all paying its short term obligations.
With a Current ratio value of 4.64, CADL perfoms like the industry average, outperforming 50.54% of the companies in the same industry.
CADL has a Quick Ratio of 4.64. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
CADL's Quick ratio of 4.64 is in line compared to the rest of the industry. CADL outperforms 51.97% of its industry peers.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.64
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CADL have decreased by -4.32% in the last year.
EPS 1Y (TTM)-4.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%148.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CADL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.22%
EPS Next 2Y1.96%
EPS Next 3Y15.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 500M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CADL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CADL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CADL's earnings are expected to grow with 15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.96%
EPS Next 3Y15.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CADL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (7/18/2025, 8:00:02 PM)

After market: 6.7023 -0.04 (-0.56%)

6.74

-0.18 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-25 2025-08-25
Inst Owners42.64%
Inst Owner Change0.82%
Ins Owners19.73%
Ins Owner Change-3.26%
Market Cap353.65M
Analysts86
Price Target21.42 (217.8%)
Short Float %15.48%
Short Ratio6.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)35.05%
Min EPS beat(2)-72.38%
Max EPS beat(2)142.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.3%
EPS NQ rev (3m)42%
EPS NY rev (1m)15.15%
EPS NY rev (3m)41.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.74
P/tB 4.74
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0
BVpS1.42
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.27%
ROE -53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.64
Altman-Z 7.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%148.11%
EPS Next Y40.22%
EPS Next 2Y1.96%
EPS Next 3Y15.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.69%
EBIT Next 3Y15.72%
EBIT Next 5Y84.59%
FCF growth 1Y23.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.43%
OCF growth 3YN/A
OCF growth 5YN/A